Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

被引：88
|
作者：
Mattes, FM
Hainsworth, EG
Hassan-Walker, AF
Burroughs, AK
Sweny, P
Griffiths, PD
Emery, VC
机构：
[1] UCL Royal Free & Univ Coll Med Sch, Div Infect & Immun, Ctr Virol, London NW3 2QG, England
[2] UCL Royal Free & Univ Coll Med Sch, Liver Transplant Unit, London, England
[3] UCL Royal Free & Univ Coll Med Sch, Renal Transplant Unit, London, England
来源：
JOURNAL OF INFECTIOUS DISEASES | 2005年 / 191卷 / 01期
基金：
英国惠康基金;
关键词：
D O I：
10.1086/425905
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The availability of valganciclovir (VGCV) has significantly simplified the treatment of human cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was no difference in the kinetics of the decrease in HCMV load after preemptive therapy with VGCV in 22 solid-organ transplant recipients (T-1/2 = 2.16 days), compared with that in 23 patients treated with intravenous ganciclovir (GCV) (T-1/2 = 1.73 days; P = .63). Preemptive therapy with VGCV pro vides control of HCMV replication that is comparable to that achieved with preemptive intravenous therapy with GCV.
引用
收藏
页码：89 / 92
页数：4
相关论文
共 50 条
  • [31] Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease
    Singh, N
    Wannstedt, C
    Keyes, L
    Gayowski, T
    Wagener, MM
    Gacciarelli, TV
    TRANSPLANTATION, 2005, 79 (01) : 85 - 90
  • [32] Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
    Blanco, Noemie Boillat
    Pascual, Manuel
    Venetz, Jean-Pierre
    Nseir, Ghaleb
    Meylan, Pascal R.
    Manuel, Oriol
    TRANSPLANTATION, 2011, 91 (02) : 251 - 255
  • [33] Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir
    Boivin, Guy
    Goyette, Nathalie
    Rollag, Halvor
    Jardine, Alan G.
    Pescovitz, Mark D.
    Asberg, Anders
    Ives, Jane
    Hortmann, Anders
    Humar, Atul
    ANTIVIRAL THERAPY, 2009, 14 (05) : 697 - 704
  • [34] Comparison of valganciclovir and oral ganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.
    Kraman, AA
    Hardwick, LL
    Filo, RS
    Govani, MV
    Milgrom, ML
    Tector, AJ
    Pescovitz, MD
    PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
  • [35] Cytomegalovirus Preemptive Monitoring Conversion and the Use of a Preemptive Threshold after Solid Organ Transplant
    Wong, C.
    Jorgenson, M.
    Descourouez, J.
    Saddler, C.
    Smith, J.
    Mandelbrot, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 807 - 807
  • [36] Erythema migrans in solid-organ transplant recipients
    Maraspin, Vera
    Cimperman, Joze
    Lotric-Furlan, Stanka
    Logar, Mateja
    Ruzic-Sabljic, Eva
    Strle, Franc
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1751 - 1754
  • [37] Cardiac operations in solid-organ transplant recipients
    Mitruka, SN
    Griffith, BP
    Kormos, RL
    Hattler, BG
    Pigula, FA
    Shapiro, R
    Fung, JJ
    Pham, SM
    ANNALS OF THORACIC SURGERY, 1997, 64 (05): : 1270 - 1278
  • [38] Influenza vaccination in solid-organ transplant recipients
    Cordero, Elisa
    Manuel, Oriol
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2012, 17 (06) : 601 - 608
  • [39] Parasitic infections in solid-organ transplant recipients
    Munoz, Patricia
    Valerio, Maricela
    Eworo, Alia
    Bouza, Emilio
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2011, 16 (06) : 565 - 575
  • [40] Response to: Polyomaviruses in solid-organ transplant recipients
    Fishman, JA
    TRANSPLANTATION, 2002, 74 (04) : 580 - 581
12345